**Document No. 00**

**Invitation to offer for NHS National Pharmaceuticals Transition 2019\_1**

**Offer reference number: CM/PHG/17/5547**

**Period of framework agreement: The total maximum duration of the framework agreement to be no more than 34 months**

**Potential periods of call-offs under the framework agreement:**

**LSNE: 01/10/2019 to 30/04/2020 (7 months)**

**CESW: 01/10/2019 to 30/09/2020 (12 months)**

**NWLN: 01/10/2019 to 28/02/2021 (17 months)**

This procurement is for a variety of drugs, we would like to bring the following information, pertinent to the specific drugs within this procurement to your attention.

This is procurement for generic drugs:

|  |
| --- |
| **CARGLUMIC ACID DISPERSIBLE TABLETS SUGAR FREE 200MG** |
| **CARGLUMIC ACID DISPERSIBLE TABLETS SUGAR FREE 200MG** |
| **CARGLUMIC ACID DISPERSIBLE TABLETS SUGAR FREE 200MG** |

For all uses except the use “for the treatment of Organic Acidaemias, including (but not restricted to) propionic, methylmalonic and isovaleric.”

This is procurement for generic drugs:

|  |
| --- |
| **DASATINIB TABLETS 100MG** |
| **DASATINIB TABLETS 140MG** |
| **DASATINIB TABLETS 20MG** |
| **DASATINIB TABLETS 50MG** |
| **DASATINIB TABLETS 70MG** |
| **DASATINIB TABLETS 80MG** |

For all uses except the use “for the treatment of CML.” (Where “CML” is understood to be the abbreviation for Chronic Myeloid Leukemia.)

This is procurement for generic drugs:

|  |
| --- |
| **EVEROLIMUS TABLET 10MG** |
| **EVEROLIMUS TABLET 2.5MG** |
| **EVEROLIMUS TABLET 5MG** |

For all uses except the:

“use of everolimus in the treatment of hormone receptor-positive, HER2/neu negative advanced **breast cancer**, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.”

“use of everolimus in the treatment of patients with **advanced renal cell carcinoma**, whose disease has progressed on or after treatment with VEGF-targeted therapy.”

“the use of everolimus in treating unresectable or metastatic, well-differentiated (Grade 1or 2) non-functional **neuroendocrine tumours of lung origin** in adults with progressive disease.”

The use of everolimus for

* “renal angiomyolipoma (AML) associated with tuberous sclerosis complex (“TSC”)
* subependymal giant cell astrocytoma (“SEGA”) associated with TSC
* refractory partial-onset seizures, with or without secondary generalization, associated with TSC (indication of dispersible tablet formulations).”

Please note that the full list of products included in the procurement are listed within Document No. 05a(i) of this Invitation to Offer pack.